10x, Harvard settle genomics patent dispute with Vizgen during trial
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
10x Genomics price target lowered to $18 from $19 at Barclays
Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...
Forbes10d
10x Genomics
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
10x Genomics, Inc. (TXG): Among Cathie Wood’s Top Stock Picks for 2025
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...
Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics today
EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...
The Victoria Advocate1mon
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...